文献速递新发突发、热带与寄生虫病

尼加拉瓜17年队列研究:无症状与有症状原发性登革病毒感染的血清理特异性流行病学模式

Serotype-specific epidemiological patterns of inapparent versus symptomatic primary dengue virus infections: a 17-year cohort study in Nicaragua.
PubMed 文献 · Lancet Infect Dis · 2024-10-25

该研究在尼加拉瓜儿童登革热队列中分析2004至2022年5931名基线无登革病毒感染者,检出1626例原发性感染(382例有症状,1244例无症状)。EDIII-MMBA血清分型总体准确率100%(95%CI 95.8-100)。无症状感染占多数,DENV3出现症状的合并比值比相较DENV1为2.13(95%CI 1.28-3.56),重症为6.75(2.01-22.62);DENV2与DENV1相似。

要点

  • 原发性登革感染以无症状为主,1244例无症状 vs 382例有症状。
  • EDIII-MMBA对无症状原发感染血清分型总体准确率100%(95%CI 95.8-100)。
  • DENV3较DENV1更易出现症状(合并OR 2.13)和重症(合并OR 6.75)。

核心结论

  • 病例监测会扭曲对登革病毒流行病学足迹的认知,无症状感染的血清理分布更复杂。
  • 不同血清型感染结局差异显著,强调需要免疫原性和有效性在各血清型间均衡的疫苗。

研究设计与样本

  • 前瞻性队列分析:尼加拉瓜儿童登革热队列研究(PDCS)2004年8月30日至2022年3月10日随访5931名基线无登革病毒感染者。
  • 以抑制ELISA或RT-PCR检出原发性DENV感染,共1626例(382例有症状,1244例无症状)。
  • 先评估EDIII-MMBA对RT-PCR或聚焦减少中和试验定性的样本进行血清分型的性能。
  • 对1244例无症状原发感染中的574例(46%)用EDIII-MMBA分析,其余结合年份和社区进行随机插补推断。

主要发现

  • EDIII-MMBA对无症状原发性DENV感染血清分型的总体准确率为100%(95%CI 95.8-100)。
  • 原发性感染以无症状为主:1244例无症状 vs 382例有症状。
  • DENV3出现症状的合并比值比相较DENV1为2.13(95%CI 1.28-3.56),重症为6.75(95%CI 2.01-22.62)。
  • DENV2在有症状和重症分析中均与DENV1相似。
  • 多个年份观察到有症状与无症状感染之间血清型分布存在年内和年际差异,以及有症状病例中未检出的血清型循环。

关键数值与推荐

  • EDIII-MMBA对无症状原发感染血清分型总体准确率100%(95%CI 95.8-100)。
  • DENV3相较DENV1出现症状的合并OR为2.13(95%CI 1.28-3.56)。
  • DENV3相较DENV1出现重症的合并OR为6.75(95%CI 2.01-22.62)。

临床怎么用

  • 作者认为病例监测会扭曲对登革病毒流行病学足迹的认知,无症状感染的血清理分布更复杂。
  • 作者认为不同血清型感染结局差异显著,强调需要免疫原性和有效性在各血清型间均衡的疫苗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dengue is the most prevalent mosquito-borne viral disease and a major public health problem worldwide. Most primary infections with the four dengue virus serotypes (DENV1-4) are inapparent; nonetheless, whether the distribution of symptomatic versus inapparent infections by serotype varies remains unknown. Here, we present (1) the evaluation of a DENV1-4 envelope domain III multiplex microsphere-based assay (EDIII-MMBA) to serotype inapparent primary infections and (2) its application leveraging 17 years of prospective sample collection from the Nicaraguan Pediatric Dengue Cohort Study (PDCS). METHODS: We analysed primary DENV infections in the PDCS from 2004 to 2022 detected by inhibition ELISA (iELISA) or RT-PCR. First, we evaluated the performance of the EDIII-MMBA for serotyping with samples characterised by RT-PCR or focus reduction neutralisation test. Next, we analysed a subset of inapparent primary DENV infections in the PDCS with the EDIII-MMBA to evaluate the epidemiology of inapparent infections. Remaining infections were inferred using stochastic imputation, taking year and neighbourhood into account. Infection incidence and percentage of inapparent, symptomatic, and severe infections were analysed by serotype. FINDINGS: Between Aug 30, 2004, and March 10, 2022, a total of 5931 DENV-naive participants were followed in the PDCS. There were 1626 primary infections (382 symptomatic, 1244 inapparent) detected by iELISA or RT-PCR over the study period. The EDIII-MMBA demonstrated excellent overall accuracy (100%, 95% CI 95·8-100) for serotyping inapparent primary DENV infections when evaluated against gold-standard serotyping methods. Of the 1244 inapparent infections, we analysed 574 (46%) using the EDIII-MMBA. We found that the majority of primary infections were inapparent, with DENV3 exhibiting the highest likelihood of symptomatic (pooled odds ratio compared with DENV1: 2·13, 95% CI 1·28-3·56) and severe (6·75, 2·01-22·62) primary infections, whereas DENV2 was similar to DENV1 in both analyses. Considerable within-year and between-year variation in serotype distribution between symptomatic and inapparent infections and circulation of serotypes undetected in symptomatic cases were observed in multiple years. INTERPRETATION: Our study indicates that case surveillance skews the perceived epidemiological footprint of DENV. We reveal a more complex and intricate pattern of serotype distribution in inapparent infections. The substantial differences in infection outcomes by serotype emphasises the need for vaccines with balanced immunogenicity and efficacy across serotypes. FUNDING: National Institute of Allergy and Infectious Diseases (National Institutes of Health) and Bill & Melinda Gates Foundation. TRANSLATION: For the Spanish translation of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bos S, Zambrana JV, Duarte E, et al. Serotype-specific epidemiological patterns of inapparent versus symptomatic primary dengue virus infections: a 17-year cohort study in Nicaragua. Lancet Infect Dis. 2024. PMID: 39489898. doi:10.1016/S1473-3099(24)00566-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。